Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023

Rhea-AI Summary

Cadrenal Therapeutics (Nasdaq: CVKD) has announced that its CEO, Quang Pham, will ring the Nasdaq Stock Market closing bell on February 8, 2023. This event commemorates the company's recent IPO and the Fast Track designation granted by the FDA for tecarfarin, a novel therapy aimed at preventing cardiac-origin blood clots in patients with end-stage renal disease and atrial fibrillation. Tecarfarin has undergone 11 clinical trials and demonstrated good tolerance among participants. The ceremony is set to be broadcast live at 3:45 p.m. ET.

Positive

• Fast Track designation by the FDA for tecarfarin
• Commemoration of the IPO with Nasdaq closing bell ceremony
• Tecarfarin shows good tolerance in clinical trials involving over 1,000 individuals

Negative

• None.

PONTE VEDRA, Fla., Feb. 8, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive Officer, Quang Pham, and other Cadrenal team members will ring the Nasdaq Stock Market closing bell on Wednesday, February 8, 2023.

"We are excited to ring the Nasdaq closing bell to commemorate our recent IPO and announcement by the U.S. Food and Drug Administration which granted a Fast Track designation to tecarfarin for the prevention of systemic thromboembolism, or more commonly referred to as blood clots, of cardiac origin in patients with end-stage renal disease and atrial fibrillation," said Quang Pham, Chief Executive Officer of Cadrenal. "These two important milestones help to advance our mission of advancing patient care in cardiorenal diseases."

The Closing Bell ceremony will be broadcast live starting at 3:45 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York City, New York. To view the broadcast, please visit: https://www.nasdaq.com/marketsite/bell-ringing-ceremony.

ABOUT CADRENAL THERAPEUTICS, INC.

Cadrenal Therapeutics is focused on developing tecarfarin, a novel cardiorenal therapy with orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to target a different pathway than the most commonly prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin has been evaluated in eleven human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2 and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com.  

Safe Harbor Statement

Any statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include statements regarding looking to advancing patient care in cardiorenal diseases.  The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to advance the program to completion, the ability to advance patient care in cardiorenal diseases and the other factors discussed in the "Risk Factors" section of the initial public offering prospectus filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Cadrenal Therapeutics specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com  

Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-ring-the-nasdaq-stock-market-closing-bell-on-february-8-2023-301741572.html

SOURCE Cadrenal Therapeutics, Inc.

FAQ

What is the significance of Cadrenal Therapeutics ringing the Nasdaq closing bell on February 8, 2023?

It marks the commemoration of their recent IPO and the FDA granting Fast Track designation to their drug tecarfarin.

What is tecarfarin and its FDA status as of February 8, 2023?

Tecarfarin is a novel cardiorenal therapy that received Fast Track designation for preventing blood clots in patients with end-stage renal disease and atrial fibrillation.

How many clinical trials has tecarfarin undergone?

Tecarfarin has been evaluated in eleven human clinical trials.

What time did the Nasdaq closing bell ceremony start on February 8, 2023?

The ceremony was broadcast live starting at 3:45 p.m. Eastern Time.